Study: mRNA Combination Vaccine Provides Protection Against COVID-19 and Influenza
Pfizer Inc and BioNTech SE announced positive results from their phase 3 clinical trial that assessed a combined mRNA vaccine candidate to protect against influenza and COVID-19 among healthy individuals aged 18 to 64 years. According to study authors, the …